02509.HK
Qyuns Therapeutics Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 16.44
−1.73%Year over year
Reported trailing growth
- Revenue
- +219.8%
- EBITDA
- +471.0%
- EBIT
- +417.8%
- EPS
- +378.9%
- Free cash flow
- +341.8%
- Operating cash flow
- +346.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +333.3%
- EBITDA
- +212.6%
- EBIT
- +198.0%
- Net income
- +191.3%
- EPS
- +189.5%
- Free cash flow
- +310.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026